

# **Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update**

<https://marketpublishers.com/r/B426355F3362EN.html>

Date: November 2022

Pages: 71

Price: US\$ 3,500.00 (Single User License)

ID: B426355F3362EN

## **Abstracts**

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### **SUMMARY**

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Bcl-2-like protein 1 is a protein encoded by the BCL2L1 gene. It belongs to BCL-2 family. It is a potent inhibitor of cell death. It inhibits activation of caspases. It regulate cell death by blocking the voltage-dependent anion channel by binding to it and preventing the release of the caspase activator (CYC1) from the mitochondrial membrane. It acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis.

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) pipeline Target constitutes close to 11 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1 and 3 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease and Musculoskeletal Disorders which include indications Solid Tumor, Non-Small Cell Lung Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Hepatocellular Carcinoma, Small-Cell Lung Cancer,

Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Bladder Cancer, Blood Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelomonocytic Leukemia (CMML), Diffuse Large B-Cell Lymphoma, Essential Thrombocythemia, Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), Fibrosis, Follicular Lymphoma, Gastric Cancer, Head And Neck Cancer, Hematological Tumor, Hormone-Sensitive Prostate Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lymphoblastic Lymphoma, Mantle Cell Lymphoma, Metastatic Melanoma, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Myelodysplastic Syndrome, Myelofibrosis, Natural Killer Cell Lymphomas, Neuroendocrine Tumors, Nodal Marginal Zone B-Cell Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Sezary Syndrome, Splenic Marginal Zone B-Cell Lymphoma, T-Cell Lymphomas and Unspecified B-Cell Lymphomas.

The latest report, outlays comprehensive information on the Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)

The report reviews Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics under development by companies and

universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics and enlists all their major and minor projects

The report assesses Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading

companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Overview

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Companies

Involved in Therapeutics Development

AbbVie Inc

Ascenta Therapeutics Inc

Ascentage Pharma Group International

AstraZeneca Plc

Dialectic Therapeutics Inc

Sirnaomics Ltd

Zentalis Pharmaceuticals Inc

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Drug Profiles

753B - Drug Profile

Product Description

Mechanism Of Action

ABT-737 - Drug Profile

Product Description

Mechanism Of Action

History of Events

AT-101 - Drug Profile

Product Description

Mechanism Of Action

History of Events

AZD-0466 - Drug Profile

Product Description  
Mechanism Of Action  
History of Events  
BCL-xL Degradar - Drug Profile  
Product Description  
Mechanism Of Action  
DT-2216 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
navitoclax dihydrochloride - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
pelcitoclax - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology and MRSA Infections - Drug Profile  
Product Description  
Mechanism Of Action  
STP-369 - Drug Profile  
Product Description  
Mechanism Of Action  
Vaccine for Hormone-Sensitive Prostate Cancer - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Dormant Products  
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Discontinued Products  
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Product Development Milestones  
Featured News & Press Releases  
Jun 10, 2022: AbbVie presents investigational Navitoclax preliminary data in JAK inhibitor Na<sup>+</sup>ve myelofibrosis patients  
Apr 28, 2022: Ascentage Pharma to present data on APG-1252 at the 2022 American Society of Clinical Oncology Annual Meeting

Apr 13, 2022: AbbVie reports positive data from Phase II myelofibrosis therapy trial

Mar 14, 2022: Dialectic Therapeutics announces DT2216 has received orphan drug designation from the FDA for the treatment of T-Cell lymphoma

Dec 14, 2021: Ascentage Pharma presents on pelcitoclax at the 63rd American Society of Hematology (ASH) Annual Meeting

Nov 04, 2021: Ascentage Pharma to release latest data from pelcitoclax including a Chinese study demonstrating complete response

Sep 13, 2021: Ascentage Pharma announces latest data of its investigational Bcl-2/Bcl-xL inhibitor pelcitoclax (APG-1252) combined with osimertinib in patients with EGFR TKI-resistant non-small cell lung cancer

Sep 08, 2021: Ascentage Pharma announces latest data of its investigational Bcl-2/Bcl-xL inhibitor Pelcitoclax (APG-1252) combined with Osimertinib in patients with EGFR TKI-resistant non-small cell lung cancer

Aug 20, 2021: Dialectic Therapeutics receives \$14.4 million Texas Company Product Development Research Award from the Cancer Prevention & Research Institute of Texas

May 19, 2021: Ascentage Pharma announces presentation on pelcitoclax at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 21, 2021: Ascentage Pharma to present data on pelcitoclax (APG-1252) at 2021 ASCO Annual Meeting

Apr 12, 2021: Ascentage Pharma releases preclinical data on Pelcitoclax at AACR Annual Meeting 2021

Mar 03, 2021: Dialectic Therapeutics receives FDA clearance of IND application for lead antiapoptotic protein targeted degradation (APTaD) candidate DT2216

Feb 09, 2021: AZD0466 clinical DEP program global expansion

Oct 08, 2020: Ascentage Pharma's apoptosis-targeting drug candidate granted Orphan Drug Designation by the US FDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2022  
Number of Products under Development by Therapy Areas, 2022  
Number of Products under Development by Indications, 2022  
Number of Products under Development by Indications, 2022 (Contd..1)  
Number of Products under Development by Indications, 2022 (Contd..2)  
Number of Products under Development by Companies, 2022  
Products under Development by Companies, 2022  
Products under Development by Companies, 2022 (Contd..1)  
Products under Development by Companies, 2022 (Contd..2)  
Products under Development by Companies, 2022 (Contd..3)  
Number of Products under Investigation by Universities/Institutes, 2022  
Products under Investigation by Universities/Institutes, 2022  
Number of Products by Stage and Mechanism of Actions, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Pipeline by AbbVie Inc, 2022  
Pipeline by Ascenta Therapeutics Inc, 2022  
Pipeline by Ascentage Pharma Group International, 2022  
Pipeline by AstraZeneca Plc, 2022  
Pipeline by Dialectic Therapeutics Inc, 2022  
Pipeline by Sirnaomics Ltd, 2022  
Pipeline by Zentalis Pharmaceuticals Inc, 2022  
Dormant Products, 2022  
Dormant Products, 2022 (Contd..1)  
Dormant Products, 2022 (Contd..2)  
Dormant Products, 2022 (Contd..3)  
Discontinued Products, 2022



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

## I would like to order

Product name: Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/B426355F3362EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B426355F3362EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970